UChicago Annual Updates from ASH 2019

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

UChicago Annual Updates from ASH 2019

Videos
Events

Playback speed

10 seconds

Updates on Myeloid Malignancies: JAK in MF, TGFb Inhibition in MF and MDS & Oral Azanucleosides in AML and MDS & IDH Inhibitors in AML & MPN

By UChicago Annual Updates from ASH 2019 FEATURING Olatoyosi Odenike

44 views

March 20, 2020

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Making the First Chance Count: Manuel

Feat. A. Ip

Videos

Hereditary Hematopoietic Malignancies: What to Look For, and What to…

UChicago Annual Updates from ASH 2019

M. Drazer

234 views

Inherited Predisposition to Myeloid Hematologic Malignancies: Why Do…

UChicago Annual Updates from ASH 2019

S. Feurstein

53 views

BCL2 Inhibition in Myeloid Malignancies: Venetoclax + Azacitidine in…

UChicago Annual Updates from ASH 2019

O. Odenike

295 views

Updates on Myeloid Malignancies: JAK in MF, TGFb Inhibition in MF an…

UChicago Annual Updates from ASH 2019

O. Odenike

44 views

Highlights from ASH on ALL: Role of AlloSCT in CR1 for Young Adults …

UChicago Annual Updates from ASH 2019

W. Stock

41 views

Highlight from ASH on ALL: Frontline Therapy in Older Adults & Dual …

UChicago Annual Updates from ASH 2019

W. Stock

33 views

Updates on CAR-T Treatment of ALL: Prognosticators of Response, Dual…

UChicago Annual Updates from ASH 2019

W. Stock

30 views

ASH 2019 Updates in Multiple Myeloma: Early Intervention in High Ris…

UChicago Annual Updates from ASH 2019

J. Jasielec

108 views

ASH 2019 Updates in R/R Multiple Myeloma: Prolonged PFS with KdD, Ve…

UChicago Annual Updates from ASH 2019

J. Jasielec

30 views

ASH 2019 Updates on CAR T Cell Therapy in DLBCL: Liso-cel has Favora…

UChicago Annual Updates from ASH 2019

P. Riedell

59 views

ASH 2019 Updates on CAR T Cell Therapy in Mantle Cell Lymphoma: KTE-…

UChicago Annual Updates from ASH 2019

P. Riedell

61 views

ASH 2019 Updates on CAR T Cell Therapy in CLL/SLL: Liso-cel Active i…

UChicago Annual Updates from ASH 2019

P. Riedell

17 views

ASH 2019 Updates on PET Directed Therapy for Early Stage DLBCL

UChicago Annual Updates from ASH 2019

J. Kline

35 views

ASH 2019 Updates on FL: Obinutuzimab + Lenalidomide in Frontline Set…

UChicago Annual Updates from ASH 2019

J. Kline

127 views

ASH 2019 Updates on Hodgkin Lymphoma: Frontline Brentuximab + Nivo i…

UChicago Annual Updates from ASH 2019

J. Kline

313 views

ASH 2019 Updates on Treatment of Young 'Fit' CLL Pts: Improved PFS a…

UChicago Annual Updates from ASH 2019

N. Jain

727 views

ASH 2019 Treatment of Older FCR Ineligible CLL Pts: 5 Years Follow‐u…

UChicago Annual Updates from ASH 2019

N. Jain

19 views

ASH 2019 Updates in R/R CLL: PFS and OS Benefit with VenR, Associati…

UChicago Annual Updates from ASH 2019

N. Jain

28 views